Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

Can cancer clinical trials be fixed?

Nature Biotechnology volume 29, pages 13–15 (2011)Cite this article

Subjects

An Erratum to this article was published on 06 May 2011

This article has been updated

As oncology drug after oncology drug fails to achieve accelerated approval, sponsors are seeking other ways to speed trials. Malorye Allison investigates.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Change history

  • 09 February 2011

    In the version of the article originally published, it was stated that “Avastin was studied in combination with Taxol in all these trials, and compared to Taxol alone.” It should have read. “Avastin was studied in combination with chemotherapy.”In addition, it stated that the FDA had rescinded approval of Avastin for metastatic breast cancer. It should have read, the FDA “recommended removal of the breast cancer indication from the Avastin label…” The errors have been corrected in the HMTL and PDF versions of the article.

References

  1. Allison, M. Nat. Biotechnol. 28, 879–880 (2010).

    Article  CAS  Google Scholar 

  2. Merrill, J. The Pink Sheet Daily, Elsevier Business Intelligence, 27 August 2010.

    Google Scholar 

  3. Vogel, C.L. et al. J. Clin. Oncol. 27 Supplement, 1017 (2009).

    Google Scholar 

  4. Mulcahy, N. Medscape Today, <http://www.medscape.com/viewarticle/703912> 4 June 2009.

    Google Scholar 

  5. Bollag, G. et al. Nature 467, 596–599 (2010).

    Article  CAS  Google Scholar 

  6. Harmon, A. The New York Times, p. 1, 18 September 2010.

    Google Scholar 

  7. Soda, M. et al. Nature 448, 561–566 (2007).

    Article  CAS  Google Scholar 

  8. Anonymous. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products (FDA, March 2004). <http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm>

  9. Anonymous. Qualification Process for Drug Development Tools. Draft Guidance (US Department of Health and Human Services, FDA, CDER, October 2010). <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf>

  10. Allison, M. Nat. Biotechnol. 28, 383–384 (2010).

    Article  CAS  Google Scholar 

  11. Richey, E.A. et al. J. Clin. Oncol. 27, 4398–4405 (2009).

    Article  CAS  Google Scholar 

  12. Lanthier, M. & Sridhara, R. J. Clin. Oncol. 28, e226 (2010).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Acton, Massachusetts

    Malorye Allison

Authors
  1. Malorye Allison
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Allison, M. Can cancer clinical trials be fixed?. Nat Biotechnol 29, 13–15 (2011). https://doi.org/10.1038/nbt.1746

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.1746

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer